Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
NCT06732258 · Sichuan University · PHASE1 · withdrawn · last registry update 2026-04-29 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering as the protection of participants.” | – | Registry record, Sichuan University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: Duke University, Alirocumab and Cemiplimab (NCT05553834)
- 2026-11-04Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against PDCD1 (NCT07915037)
- 2026-11-02Also stopped (withdrawn): CureVac, CV09070101 mRNA vaccine (CVHNLC) 50 µg + CV09070101 mRNA vaccine (CVHNLC) 100 µg (NCT07073183)
- 2026-11-02Also stopped (withdrawn): Genmab, Petosemtamab + Pembrolizumab (NCT07353957)
- 2026-10-29Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + MK-4830 (NCT04165083)
- 2026-10-28Results posted on the registry: Immedica Pharma AB, Pegzilarginase + Pembrolizumab (NCT03371979)
- 2026-10-28Also stopped (terminated): Immedica Pharma AB, Pegzilarginase + Pembrolizumab (NCT03371979)
- 2026-08-20Phase 3 first posted: Revolution Medicines, Inc., zoldonrasib + Placebo (NCT07777822)
- 2026-08-10Phase 3 first posted: AbbVie, ABBV-1480 + Pembrolizumab (NCT07756645)
- 2026-07-20Phase 3 first posted: AIO-Studien-gGmbH, Tislelizumab + Tislelizumab Combined With Chemotherapy (NCT07715396)
- 2026-04-21Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT07541170)
- 2026-04-07Phase 3 first posted: Merck Sharp & Dohme LLC, Intismeran + Pembrolizumab coformulated with berahyaluronidase alfa (NCT07513376)
- 2026-02-25Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + MK-3475A (NCT07431827)
- 2026-01-26Phase 3 first posted: Eikon Therapeutics, EIK1001 + Pembrolizumab (KEYTRUDA®) (NCT07365319)
- 2026-01-23Phase 3 first posted: Bristol-Myers Squibb, Pumitamig + Pembrolizumab (NCT07361510)
- 2025-09-29Phase 3 first posted: Boehringer Ingelheim, Zongertinib + Pembrolizumab (NCT07195695)
- 2025-09-24Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Pembrolizumab (+) Berahyaluronidase alfa (NCT07190248)
- 2025-09-09Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL2107 + Keytruda® (NCT07162883)
- 2025-07-14Phase 3 first posted: Bristol-Myers Squibb, BMS-986504 + Pembrolizumab (NCT07063745)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision